Notably, hBD-GCs appear to be more numerous under pathological conditions, such as hypoxia-ischemia [12], experimentally induced epilepsy [13], and pharmacoresistant temporal lobe epilepsy of humans [14]. This evidence concerns the gene HBD and epilepsy.